Log in

Helius Medical Technologies Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $0.42
50-Day Range
MA: $0.47
52-Week Range
Now: $0.42
Volume231,128 shs
Average Volume679,301 shs
Market Capitalization$18.84 million
P/E RatioN/A
Dividend YieldN/A
Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain's ability to compensate for damage due to trauma or disease. The Company's PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.
Read More
Helius Medical Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:HSDT



Sales & Book Value

Annual SalesN/A



Market Cap$18.84 million
Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HSDT News and Ratings via Email

Sign-up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Helius Medical Technologies (OTCMKTS:HSDT) Frequently Asked Questions

How has Helius Medical Technologies' stock price been impacted by COVID-19 (Coronavirus)?

Helius Medical Technologies' stock was trading at $0.5401 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSDT stock has decreased by 22.7% and is now trading at $0.4176.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Helius Medical Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Helius Medical Technologies

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies Inc (OTCMKTS:HSDT) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04. The business had revenue of $0.13 million for the quarter, compared to analysts' expectations of $0.10 million.
View Helius Medical Technologies' earnings history

What guidance has Helius Medical Technologies issued on next quarter's earnings?

Helius Medical Technologies issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $100K - 100K.

Who are some of Helius Medical Technologies' key competitors?

What other stocks do shareholders of Helius Medical Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Helius Medical Technologies investors own include Mazor Robotics (MZOR), Coty (COTY), Matinas BioPharma (MTNB), Boxlight (BOXL), Opko Health (OPK), Actinium Pharmaceuticals (ATNM), Energy Transfer LP Unit (ET), Remark (MARK), Acasti Pharma (ACST) and BIOLASE (BIOL).

Who are Helius Medical Technologies' key executives?

Helius Medical Technologies' management team includes the following people:
  • Philippe Deschamps, President, Chief Executive Officer, Director
  • Joyce N. LaViscount, Chief Financial Officer, Chief Operating Officer
  • Brian Bapty, Vice President, Strategy and Business Development
  • Jonathan Sackier, Chief Medical Officer
  • Dane Andreeff, Director
  • Huaizheng Peng, Director
  • Mitch Eugene Tyler, Director
  • Thomas E. Griffin, Independent Director
  • Edward M. Straw, Independent Director

What is Helius Medical Technologies' stock symbol?

Helius Medical Technologies trades on the OTCMKTS under the ticker symbol "HSDT."

Who are Helius Medical Technologies' major shareholders?

Helius Medical Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Camelot Portfolios LLC (0.22%).
View institutional ownership trends for Helius Medical Technologies

Which major investors are buying Helius Medical Technologies stock?

HSDT stock was bought by a variety of institutional investors in the last quarter, including Camelot Portfolios LLC.
View insider buying and selling activity for Helius Medical Technologies

How do I buy shares of Helius Medical Technologies?

Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Helius Medical Technologies' stock price today?

One share of HSDT stock can currently be purchased for approximately $0.42.

How big of a company is Helius Medical Technologies?

Helius Medical Technologies has a market capitalization of $18.84 million.

What is Helius Medical Technologies' official website?

The official website for Helius Medical Technologies is www.heliusmedical.com.

How can I contact Helius Medical Technologies?

Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at 215-944-6100 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.